Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe maximum weight loss seen with Wegovy (semaglutide 2.4 mg) in clinical trials was around 15% of body weight over 68 weeks, based on the STEP 1 trial published in the New England Journal of Medicine. That figure is a trial average — some participants lost more, some lost less, and what any individual achieves depends on their biology, how long they stay on treatment, and the lifestyle changes they make alongside it. Wegovy is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is clinically appropriate for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A lot of people arrive at this question having seen a headline figure ("lose up to 15%" or, more recently, "nearly 21%") and treat it as a personal forecast. It is understandable. The numbers are striking, and the research behind them is rigorous. But a trial average is a population midpoint, not a promise. In the STEP 1 study, participants ranged from modest losses to well above the headline figure. Some lost very little. That range is the honest picture, and it matters far more than a single quoted percentage.
Letting go of the idea that maximum means guaranteed is actually freeing. It shifts the question from "will I hit the ceiling?" to "what gives me the best chance of a meaningful result?", which is a much more useful thing to explore with a prescriber.
The full picture of weight loss on Wegovy covers how results vary across the dose schedule and what the wider STEP trial programme found about different patient groups.
The 15% figure comes from the 2.4 mg weekly maintenance dose, which was Wegovy's standard for several years. On 14 April 2026 the MHRA approved a dedicated single-dose 7.2 mg pen, and the accompanying trial data reported approximately 20.7% average weight loss over 72 weeks. That is a substantial step up. For context, the NICE appraisal of tirzepatide (TA1026) noted that indirect comparisons place tirzepatide ahead of semaglutide 2.4 mg, the 7.2 mg data narrows that gap considerably.
What this means in practice: the dose your prescriber eventually reaches with you is one of the strongest levers on your outcome. Starting at 0.25 mg and titrating carefully is not a slow route to results, it is the route. Rushing the schedule tends to increase side effects, which can interrupt treatment and undermine progress. The titration exists for a reason.
If you are curious about how long Wegovy takes to produce noticeable changes, the early weeks tend to reflect tolerance rather than maximum effect.
Biology plays a larger role than most people expect. Baseline weight, insulin sensitivity, gut-hormone response and genetic variation in GLP-1 receptor activity all influence how much semaglutide shifts the appetite set-point. These are not things a person can simply override with more effort.
That said, a few modifiable factors do move the needle. Adequate protein intake helps preserve muscle as weight falls, important because muscle determines how much energy you burn at rest. Staying well hydrated offsets some of the nausea that leads people to eat very little of anything, which can backfire. Consistent movement, even walking, compounds the effect. None of this is about willpower; it is about giving the medicine the conditions in which it works best. If you want to understand how to maximize weight loss on Wegovy, our practical guidance goes into each of these areas in detail.
Weight is shaped by biology, not character. That is worth holding onto if progress feels slower than you hoped.
Most people experience a slowing of weight loss after the initial months, even on the full maintenance dose. This is normal, the body adapts, and a plateau is not the same as treatment failure. NICE guidance on semaglutide notes that if less than 5% weight has been lost after six months at the maintenance dose, continuing should be reviewed. That review is a clinical conversation, not an automatic stop.
If you are seeing little movement, the first questions worth exploring with your prescriber are whether the titration is complete, whether GI side effects have been suppressing food intake in an unsustainable way, and whether there are any lifestyle factors that could shift. A record of why weight loss can stall on Wegovy covers the most common clinical reasons in plain language.
Cost is a real consideration for anyone on a longer course of treatment. A straightforward comparison of what different providers include in their pricing is at Wegovy price comparison UK, worth reading before committing to any service.
If you would like to discuss your own situation with a prescriber, check your eligibility for a free consultation with our clinical team.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.